Telix Pharmaceuticals Ltd (TLPPF) Full Year 2025 Earnings Call Highlights: Robust Revenue …

GuruFocus News

Fri, February 20, 2026 at 2:04 PM GMT+9 4 min read

In this article:

TLX

+4.68%

This article first appeared on GuruFocus.

**Revenue:** $804 million, a 56% growth year-over-year.

**Precision Medicine Revenue:** $622 million, up 22% year-over-year.

**EBITDA:** Improved by 25% to $216 million.

**Gross Margin:** 53%, consistent with the first half performance.

**Cash Balance:** $142 million at year-end.

**R&D Investment:** $157 million, focused on late-stage pipeline.

**General and Administration Expenses:** Decreased to 12% of revenue from 17% last year.

**Adjusted Earnings:** $39.5 million, in line with market consensus.

**2026 Revenue Guidance:** $950 to $970 million, implying up to 25% growth in precision medicine business.

**2026 R&D Investment Guidance:** $200 to $240 million.

Warning! GuruFocus has detected 6 Warning Sign with TLPPF.

Is TLPPF fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 19, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Telix Pharmaceuticals Ltd (TLPPF) reported a 56% growth in revenue to $804 million, marking the third consecutive year of double-digit revenue growth.

The precision medicine business saw a 22% year-over-year increase in revenue, with EBITDA improving by 25% to $216 million.

The company successfully launched Gozelix, which has been FDA approved and is expected to drive future revenue growth.

Telix Pharmaceuticals Ltd (TLPPF) has a robust pipeline with over 30 sponsored and collaborative studies, including pivotal trials that are expected to generate significant commercial and financial inflection points.

The company maintains a solid cash balance of $142 million, allowing it to self-fund R&D investments and commercial infrastructure without shareholder dilution.

Negative Points

The European market for Telix Pharmaceuticals Ltd (TLPPF)'s products is experiencing delays due to the complex reimbursement landscape, which can take 9 to 12 months post-approval.

Gross margins for the RLS business segment are lower due to the commoditized nature of third-party nuclear medicine products.

The company faces ongoing competitive pressure in the precision medicine market, which could impact future growth.

There are uncertainties regarding the timeline for FDA review and approval of new products, which could affect the launch schedule.

Telix Pharmaceuticals Ltd (TLPPF) plans to reinvest earnings into R&D and commercial expansion, potentially impacting short-term profitability.

Q & A Highlights

Q: When can we expect to see safety data for the 59 study, and what are the next steps with the FDA? A: We have had an independent data safety review board that has reviewed the data and progressed to randomization. We need to complete the clinical case report forms and validate the data before submitting it to the FDA. Once available, we will simultaneously disclose it and submit it to the FDA. We are not waiting on anything from the FDA; it’s all on the company side, and you will not have long to wait. - Christian Behrenbruch, CEO

Story Continues  

Q: Can you elaborate on the two-product strategy for Aus6 and Goelic and how it will drive 25% growth in precision medicine revenue? A: The two-product strategy allows us to manage economic needs and preferences for reimbursed versus non-reimbursed products. It helps us navigate the changing reimbursement environment and manage ASP as CMS evolves. This strategy provides options without locking down a singular product. - Kevin Richardson, CEO of Precision Medicine

Q: How does the European market for Aluix and Gazellics compare to the US, and what are the challenges? A: The European market has a different reimbursement landscape, with delays between product approval and reimbursement. There are no material sales until reimbursement is secured, which can take 9 to 12 months. We have only just received reimbursement in some EU countries, and we are executing market launches now. - Christian Behrenbruch, CEO and Kevin Richardson, CEO of Precision Medicine

Q: What are the key drivers for gross margin improvement, especially for the RLS business? A: The RLS segment reports third-party products, which have lower margins. Our products through RLS are captured in the precision medicine segment, which maintains mid-60% margins. As more of our product volume goes through our in-house pharmacy network, the gross margin has the potential to improve towards 70%. - Christian Behrenbruch, CEO

Q: What is the timeline for the part two interim analysis of the Prospect Global study? A: The part two study is recruiting well, and the interim analysis is based on about 80 to 90 events. We expect the futility analysis to read out in Q4 of this year, based on the current recruitment trajectory. - Christian Behrenbruch, CEO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info